Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study

Autor: Rosenthal, Mark, Clement, Paul M., Campone, Mario, Gil-Gil, Miguel J., DeGroot, John, Chinot, Olivier, Idbaih, Ahmed, Gan, Hui, Raizer, Jeffrey, Wen, Patrick Yung, Pineda, Estela, Donnet, Valerie, Mills, David, El-Hashimy, Mona, Mason, Warren

Publikováno v: In ESMO Open 2020 5(4)

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.

Autor: Rodon J; Molecular Therapeutics Research Unit, Department of Medical Oncology, Vall d'Hebron University Hospital, Centro Cellex, 08035, Barcelona, Spain., Curigliano G; Division of Early Drug Development for Innovative Therapies, Department of Hematology and Oncology, University of Milano, Istituto Europeo di Oncologia, 20141, Milan, Italy., Delord JP; Clinical Research Unit, Institut Claudius Regaud, 31052, Toulouse, France., Harb W; Horizon Oncology Center, 47905, Lafayette, IN, USA., Azaro A; Molecular Therapeutics Research Unit, Department of Medical Oncology, Vall d'Hebron University Hospital, Centro Cellex, 08035, Barcelona, Spain., Han Y; Novartis Pharmaceuticals Corporation, 07936, East Hanover, NJ, USA., Wilke C; Novartis Pharma AG, Postfach, CH-4002, Basel, Switzerland., Donnet V; Novartis Pharma S.A.S., 92506, Rueil-Malmaison, France., Sellami D; Novartis Pharmaceuticals Corporation, 07936, East Hanover, NJ, USA., Beck T; Highlands Oncology Group, 72703, Fayetteville, AR, USA.

Publikováno v: Oncotarget [Oncotarget] 2018 Aug 03; Vol. 9 (60), pp. 31709-31718. Date of Electronic Publication: 2018 Aug 03 (Print Publication: 2018).